Hemorrhagic disease of newborn
Reading File
Finding Sources
Finding Sources
Searching PubMed
"hemorrhagic disease of the newborn" OR "vitamin K deficiency bleeding" newborn
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Hemorrhagic Disease of the Newborn (HDN) / Vitamin K Deficiency Bleeding (VKDB)
Definition and Nomenclature
Hemorrhagic disease of the newborn (HDN) is a neonatal bleeding coagulopathy caused by a transitory deficiency of vitamin K-dependent clotting factors. The modern preferred term is vitamin K deficiency bleeding (VKDB), as the underlying mechanism is specifically vitamin K deficiency rather than a general hemorrhagic condition. - Tintinalli's Emergency Medicine
Pathophysiology
Vitamin K-Dependent Clotting Factors
Vitamin K is required for the gamma-carboxylation of glutamic acid residues on clotting factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S. Without this carboxylation, these factors cannot bind calcium ions and are functionally inert (called PIVKA - Proteins Induced by Vitamin K Absence or Antagonism). PIVKA-II (undercarboxylated, non-functional prothrombin) is elevated in vitamin K deficiency and is a confirmatory marker. - Tietz Textbook of Laboratory Medicine
Why Newborns are Deficient
Neonates are uniquely vulnerable due to a combination of factors:
| Factor | Explanation |
|---|---|
| Poor placental transfer | Vitamin K crosses the placenta poorly |
| Sterile gut at birth | No intestinal bacteria to synthesize vitamin K (menaquinones) initially |
| Low liver stores | Hepatic vitamin K stores are minimal at birth |
| Breast milk | Human milk provides only ~1/5 of the daily vitamin K requirement; cow's milk formulas are supplemented |
| Short half-life | Vitamin K has a short metabolic half-life |
Measurements of non-gamma-carboxylated prothrombin suggest vitamin K deficiency occurs in about 3% of live births without prophylaxis. - Goodman & Gilman's Pharmacological Basis of Therapeutics
Classification: Three Forms
| Form | Onset | Characteristic Features | Risk Factors |
|---|---|---|---|
| Early | Within 24 hours of birth | Cephalhematoma, intracranial hemorrhage, intrathoracic/intraabdominal bleeding | Maternal drugs (warfarin, phenytoin, isoniazid, rifampicin, cephalosporins) |
| Classic | Days 2-14 (2nd to 7th day most common) | Umbilical bleeding, circumcision site oozing, GI bleeding, ecchymoses | Breastfeeding, inadequate vitamin K stores |
| Late | 2-12 weeks (up to 6 months) | Often intracranial hemorrhage (most dangerous) | Exclusively breastfed, malabsorption, hepatobiliary disease, absent/refused prophylaxis |
Classic HDN usually presents in the first postnatal week. Late VKDB occurs from 2 to 24 weeks and has been most frequently attributed to inadequate or absent vitamin K prophylaxis. - Tietz Textbook of Laboratory Medicine
Clinical Presentation
Bleeding manifestations range from mild to life-threatening:
- Mild: Oozing from the umbilical stump, circumcision site, venipuncture sites, ecchymoses
- Moderate: Gastrointestinal bleeding (melena, hematemesis), cephalhematoma
- Severe/Life-threatening: Pulmonary hemorrhage, intracranial hemorrhage (ICH)
In developed countries with prophylaxis programs, 30%-60% of reported VKDB cases are associated with intracranial hemorrhage - a key reason for aggressive prophylaxis. - Tintinalli's Emergency Medicine
Risk Factors
- Breastfeeding (low vitamin K in human milk)
- Malabsorption or hepatobiliary disorders (cholestasis impairs fat-soluble vitamin absorption)
- Maternal medications: phenytoin, isoniazid, warfarin, anticonvulsants, certain cephalosporins (e.g., cefamandole)
- Lack of vitamin K prophylaxis at birth
- Home delivery without administration of vitamin K
- Countries with limited healthcare access
Laboratory Findings
- Prolonged PT (prothrombin time) - reflects deficiency of factors II, VII, X
- Prolonged aPTT (activated partial thromboplastin time) - reflects deficiency of factors II, IX, X
- Normal thrombin time (TT) and normal fibrinogen - distinguishes VKDB from DIC
- Normal platelet count
- Decreased hematocrit (proportional to blood loss)
- Elevated PIVKA-II (confirmatory marker)
- Measuring multiple vitamin K-dependent factors (vs. non-vitamin K-dependent factors) confirms the diagnosis
Diagnosis
- Clinical presentation in appropriate context (neonatal age, breastfed, no prophylaxis)
- Coagulation profile as above
- Response to vitamin K administration: factor levels normalize within ~6 hours; this therapeutic response is both diagnostic and curative
- PIVKA-II measurement if diagnosis uncertain
Treatment
Acute Treatment
| Scenario | Treatment |
|---|---|
| Active bleeding (any severity) | Immediate 1 mg vitamin K (phytonadione) SC, IM, or IV |
| Life-threatening hemorrhage | FFP 10-20 mL/kg + vitamin K (do not wait for labs if ICH suspected) |
| Severe hemorrhage (INR not quickly reversible) | Prothrombin complex concentrate (PCC) as adjunct |
- IM route: Risk of significant hematoma at injection site
- IV route: Risk of anaphylactoid reaction (give slowly)
- The IV route corrects coagulation within about 6 hours
Do not wait for laboratory results if clinical suspicion of intracranial bleeding is high. - Tintinalli's Emergency Medicine
If the mother received warfarin or anticonvulsants, the dose may need to be increased or repeated. Some clinicians treat mothers on anticonvulsants with oral vitamin K 20 mg/day for 2 weeks before delivery. - Goodman & Gilman's
Prophylaxis
The American Academy of Pediatrics (AAP) has recommended intramuscular vitamin K prophylaxis as standard of care since 1961. Routine prophylaxis is required by law in the United States.
| Route | Dose | Notes |
|---|---|---|
| IM (preferred) | 0.5-1.0 mg phytonadione at birth | Most effective; prevents both early and late VKDB |
| Oral | Multiple-dose regimens | Less effective than IM for preventing late VKDB; used in countries/families where IM refused |
IM vitamin K is more effective than oral administration for preventing late hemorrhagic disease. - Textbook of Family Medicine, 9e
There has been an increasing rate of parental refusal in the past decade - an important public health concern leading to recurrence of late VKDB cases. - Tintinalli's Emergency Medicine; see also the Neonatologists and vitamin K hesitancy review (2023)
Key Points for Clinical Practice
- VKDB is the modern preferred term for hemorrhagic disease of the newborn
- All infants are born functionally vitamin K deficient; formula-fed babies rarely develop VKDB because formulas are supplemented
- Breastfed infants without prophylaxis are at highest risk - especially for late VKDB with ICH
- The classic lab pattern: prolonged PT + prolonged aPTT + normal TT + normal platelets + normal fibrinogen
- Menadione (synthetic vitamin K3) is no longer used - it caused hemolytic anemia and jaundice in infants
- Intracranial hemorrhage in a neonate with a coagulopathy should always prompt evaluation and treatment for VKDB
Sources: Bradley and Daroff's Neurology in Clinical Practice | Tintinalli's Emergency Medicine | Goodman & Gilman's Pharmacological Basis of Therapeutics | Tietz Textbook of Laboratory Medicine, 7th Ed | Textbook of Family Medicine, 9e | Lippincott Illustrated Reviews: Biochemistry, 8th Ed
This is a shared conversation. Sign in to Orris to start your own chat.